Propeller Health announced Tuesday an agreement to develop and manufacture a custom sensor for GlaxoSmithKline's Ellipta dry powder inhaler for use in certain clinical trials in asthma and chronic obstructive pulmonary disease (COPD).
According to Propeller Health, "the sensor technology will be used to provide greater insights into adherence patterns…and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes." Dave Allen, GlaxoSmithKline's senior vice president of respiratory R&D, added that using "sensor technology to improve the quality of adherence data collected during our studies will advance our understanding of disease and inform our decision-making in the development of new medicines."
Specifically, Propeller Health noted that the sensor will automatically collect and record data on the Ellipta inhaler's usage, such as the date and time of each use, and wirelessly transmit the information to a central data source for analysis by GlaxoSmithKline's researchers. Under the agreement, of which financial terms were not revealed, GlaxoSmithKline retains an option to negotiate exclusive commercialisation rights to the sensor for use with its marketed portfolio of drugs administered using the Ellipta inhaler.
In July, Propeller Health said the FDA granted 510(k) clearance for its Propeller digital health platform in association with drugs using GlaxoSmithKline's Diskus dry powder inhaler for asthma and COPD, after having gained similar clearance of the platform in March for medications using Boehringer Ingelheim's Respimat inhaler for COPD.
For more information on patient adherence, see Trends and Innovations in Patient Adherence.
To read more Top Story articles, click here.